AlphAIalphai — Financial news for AI agents
investing.comSEP 12 min read$AMGN

UK regulator suspends Amgen rare-disease drug Tavneos for new patients

UK's MHRA suspended Amgen's drug Tavneos for new patients, citing unreliable data in the main study. The regulator plans to revoke UK approval by March 2027. Amgen disagrees, citing additional clinical trial evidence. The European Commission also revoked approval in August. Amgen acquired the drug's developer, ChemoCentryx, in 2022 for $3.7 billion.

Original reporting
investing.com
Published Sep 1, 2026, 3:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 4:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefRegulation
Primary signal
$AMGN
Bearish
high confidence
Mentioned
$AMGN
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$AMGNBearishHigh
01

Why it matters

The suspension removes UK market access, likely pressuring Amgen's share price and prompting investors to reassess rare‑disease drug exposure.

02

Market read

Regulatory action on a high‑profile rare‑disease drug creates immediate trading risk for Amgen.

03

What to watch

Potential for rapid regulatory reinstatement if data concerns are addressed.

Relevance 8/10Novelty 8/10Timing: today

Background

The MHRA's decision follows a prior EU revocation of Tavneos approval due to unreliable trial data.

Company-level read

Ticker impact

$AMGNBearishHigh confidence
Context

UK regulator suspended sale of Amgen's rare‑disease drug Tavneos to new patients, citing unreliable trial data.

Expected impact

downward pressure

Evidence & confidence

Regulatory suspension removes a revenue stream and may trigger broader concerns about the drug's data integrity.

Market effects

Sector

Biotech sector may face heightened scrutiny on trial data.

Regional

UK biotech stocks could see short‑term weakness.

Global

Limited to Amgen and peers with similar rare‑disease pipelines.

Counterpoint

What could challenge this read

Amgen may retain strong US sales and could mitigate UK loss.

Key entities

  • Company
    Amgen

    US biotech firm holding global rights to Tavneos.

  • Regulator
    MHRA

    UK Medicines and Healthcare products Regulatory Agency.

Read at source← All news

Related articles

AUG 31
$AMGNMed

Trump Announces New Drug Pricing Deals With Nine Manufacturers

President Trump announced new voluntary drug pricing agreements with nine pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Merck, to lower U.S. prescription drug prices. The deals, part of the TrumpRx platform, aim to align prices with those in other wealthy nations. Companies receive tariff relief in exchange for participation. Critics note limited impact on patient costs and lack of public contract details.

vinnews.com2 min
AUG 31
$AMGNHighAI 9/10

Amgen's Repatha Cuts Death Risk 20% In High-Risk Patients Without Prior Heart Attack Or Stroke

Amgen (AMGN) reported that its drug Repatha reduced death risk by 20% in high-risk patients without prior heart attack or stroke, per Phase 3 trial data. The study, involving 12,000+ patients, also showed reductions in cardiovascular events. Repatha is approved in 75 countries and used by 9M patients globally. AMGN stock closed at $432.42 on Friday, up 0.95% in pre-market trading.

rttnews.com2 min
AUG 31
$AMGNHighAI 9/10

AMGN Looks 18.3% Overvalued on GF Value™ as Dividend Sustainabil

Amgen (AMGN) reported Phase 3 trial results showing its drug Repatha reduced mortality risk by 20%. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year growth rate. AMGN's stock trades 18.3% above its GF Value™ of $365.50, with a GF Score™ of 79. Insider activity shows $29.3M in sales, while institutional gurus show a slight net trimming trend.

gurufocus.com3 min
AUG 31
$AMGNMedAI 8/10

AMGN Looks 18.3% Overvalued on GF Value™

Amgen (AMGN) reported that its drug Repatha reduced mortality risk in high-risk patients, per a clinical trial. The company offers a 2.3% dividend yield with a 44% payout ratio and a 7.1% 3-year dividend growth rate. AMGN's stock trades 18.3% above its GF Value™, with a GF Score™ of 79. Insider sales totaled $29.3M over the past year, while institutional investors show mixed sentiment.

gurufocus.com3 min
AUG 31
$AMGNMedAI 9/10

Repatha Significantly Reduces Mortality Risk in High-Risk Patients

Amgen's Repatha (evolocumab) showed a 20% reduction in mortality risk in a Phase 3 trial with 12,000 high-risk patients, potentially changing cardiovascular treatment practices. The drug also reduced heart attacks and strokes. Amgen reported $36.7B in 2025 revenue, up 9.9% YoY, with a 21% net margin. Analysts forecast AMGN stock to fall, with a current price of $436.99.

intellectia.ai2 min